Among the human T-lymphotropic virus (HTLV) types, HTLV-1 is the most prevalent, and it
has been linked to a spectrum of diseases, including HAM/TSP, ATLL, and hyperinfection …

Human T cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T cell
leukemia/lymphoma (ATL), HTLV-1 associated myelopathy (HAM/TSP), and of a number of …

Human T-cell leukemia virus type-1 (HTLV-1) causes adult T-cell leukemia/lymphoma (ATL).
HTLV-1 carriers have a lifelong asymptomatic balance between infected cells and host …

Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by latent
infection of human T-cell lymphotropic virus type 1. The outcome for ATLL is very poor, with …

Adult T-cell leukemia-lymphoma (ATL) is a distinct peripheral T-lymphocytic malignancy
etiologically associated with human T-cell lymphotropic virus type I. The diversity in clinical …

The human T-cell lymphotropic (or leukemia) virus type-1 (HTLV-1) was isolated by Poiesz
et al. in 1980 from the T-cell line Hut-102, established from a patient thought to have …

Adult T-cell leukemia/lymphoma (ATLL), an infrequent malignancy resultant from human T-
cell lymphotropic virus type I (HTLV-1), exhibits a spectrum of phenotypes, encompassing …

Direct growth inhibition of infectious organisms coupled with immunomodulation to
counteract the immunosuppressive environment might be a beneficial therapeutic approach …

Human T-cell leukemia virus type 1 (HTLV-1) was the first human retrovirus discovered. It is
estimated that 10–20 million people are infected worldwide by this oncogenic virus. About 5 …

With current drug treatments failing due to toxicity, low efficacy and resistance; leishmaniasis
is a major global health challenge that desperately needs new validated drug targets …